A pioneering CAR-T program is redefining treatment for relapsed/refractory B-cell non-Hodgkin lymphoma. Join leading scientists as they share exclusive data and lessons learned from New Zealand’s first CD19-specific CAR-T cell therapy program. Explore how a third-generation CAR design with a TLR2 domain is delivering promising clinical outcomes–while being manufactured on an automated, closed system platform.
This webinar will discuss the scalable manufacturing of CAR-T cells and provide clinical data and guidance on achieving commercialization of CAR-T in New Zealand.
You have registered for this webinar